ciglitazone has been researched along with Pneumococcal Infections in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.
Excerpt | Relevance | Reference |
---|---|---|
" Because patients with type 2 diabetes have an increased risk for pneumonia, we evaluated the influence of ciglitazone, a TZD, on markers of inflammation and outcome during pneumonia caused by Streptococcus pneumoniae." | 7.75 | The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice. ( de Vos, AF; Florquin, S; Stegenga, ME; van der Poll, T, 2009) |
" Because patients with type 2 diabetes have an increased risk for pneumonia, we evaluated the influence of ciglitazone, a TZD, on markers of inflammation and outcome during pneumonia caused by Streptococcus pneumoniae." | 3.75 | The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice. ( de Vos, AF; Florquin, S; Stegenga, ME; van der Poll, T, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Stegenga, ME | 1 |
Florquin, S | 1 |
de Vos, AF | 1 |
van der Poll, T | 1 |
1 other study available for ciglitazone and Pneumococcal Infections
Article | Year |
---|---|
The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice.
Topics: Animals; Colony Count, Microbial; Cytokines; Female; Hypoglycemic Agents; Inflammation; Lung; Mice; | 2009 |